Background: Basal cell carcinoma (BCC) is a frequently diagnosed skin cancer with variable histopathological types. BCC was not widely studied in Sudan as it is in the Caucasian population. Objectives: To appraise the clinical and histopathological aspects of BCC of the skin in Sudan. Materials and methods: A retrospective descriptive analysis of 84 histologically diagnosed BCC specimens seen at three hospitals in four-year duration were reviewed and classified into histological variants according to the WHO classification 2006. Data were analyzed using Statistical Package for the Social Sciences, version 23.0. Results: The mean age (±SD) of the study participants was 56 (±1.75) years, ranging from 20 to 92 years and 63.1% were females (Female to male ratio 1.7:1). The most common incidence was among the age group 51 - 60 years. The face was the primary tumor site in 89.3% with a predilection for the nasal area (31% of those in the face), followed by the trunk (6%). Out of the total, 54.8% were histologically categorized as nodular/solid, while infiltrative accounts for 11.9% followed by the superficial type (8.3%). Surgical margins were involved in 34.5% of cases and peri-neural invasion was seen in 3.6% of cases, mostly were of the infiltrative variant. Conclusion: BCC in Sudan is commonly present in the head as solid nodular histopathological variant which is correlated with worldwide distribution but has slightly younger age and female predominance; thus further studies are needed to assess risk factors in Sudanese patients and improve approaches for earlier diagnosis and better management.
References
[1]
Murkey, N., Murkey, P., Kalele, K.P. and Patil, K.P. (2017) Adenoid Variant of Basal Cell Carcinoma: A Case Report with a Glance at Biological Behavior of the Tumor. Indian Journal of Dermatology, 62, 103-105.
https://doi.org/10.4103/0019-5154.198053
[2]
Saxena, K., Manohar, V., Bhakhar, V. and Bahl, S. (2016) Adenoid Basal Cell Carcinoma: A Rare Facet of Basal Cell Carcinoma. BMJ Case Reports, 2016, Article ID: 10 1136/bcr-2015-214166.
[3]
Copeland, G., et al. (2009) Cancer in North America: 2002-2006. Volume Three: Registry-Specific Cancer Mortality in the United States. North American Association of Central Cancer Registries Inc., Springfield.
[4]
Lomas, A., Leonardi-Bee, J. and Bath-Hextall, F. (2012) A Systematic Review of Worldwide Incidence of Nonmelanoma Skin Cancer. The British Journal of Dermatology, 166, 1069-1080. https://doi.org/10.1111/j.1365-2133.2012.10830.x
[5]
Raasch, B.A. and Buettner, P.G. (2002) Multiple Nonmelanoma Skin Cancer in an Exposed Australian Population. International Journal of Dermatology, 41, 652-658.
https://doi.org/10.1046/j.1365-4362.2002.01573.x
[6]
Rubin, A.I., Chen, E.H. and Ratner, D. (2005) Basal-Cell Carcinoma. The New England Journal of Medicine, 353, 2262-2269. https://doi.org/10.1056/NEJMra044151
[7]
Cohen, P.R. (2017) Red Dot Basal Cell Carcinoma: Report of Cases and Review of This Unique Presentation of Basal Cell Carcinoma. Cureus, 9, e1110.
https://doi.org/10.7759/cureus.1110
[8]
Kaskel, P., et al. (2015) Ultraviolet Exposure and Risk of Melanoma and Basal Cell Carcinoma in Ulm and Dresden, Germany. Journal of the European Academy of Dermatology and Venereology: JEADV, 29, 134-142.
https://doi.org/10.1111/jdv.12488
[9]
Malik, M.O., Hidaytalla, A., Daoud, E.H. and El-Hassan, A.M. (1974) Superficial Cancer in the Sudan. A Study of 1225 Primary Malignant Superficial Tumours. British Journal of Cancer, 30, 355-364. https://doi.org/10.1038/bjc.1974.205
[10]
Wehner, M.R., et al. (2012) Indoor Tanning and Non-Melanoma Skin Cancer: Systematic Review and Meta-Analysis. Bmj, 345, e5909.
https://doi.org/10.1136/bmj.e5909
[11]
Leiter, U., Eigentler, T. and Garbe, C. (2014) Epidemiology of Skin Cancer. Advances in Experimental Medicine and Biology, 810, 120-140.
https://doi.org/10.1007/978-1-4939-0437-2_7
[12]
Lipozencic, J., et al. (2010) Skin Cancers in Croatia, 2003-2005: Epidemiological Study. Collegium Antropologicum, 34, 865-869.
[13]
Kim, H.S., et al. (2010) Recent Trend in the Incidence of Premalignant and Malignant Skin Lesions in Korea between 1991 and 2006. Journal of Korean Medical Science, 25, 924-929. https://doi.org/10.3346/jkms.2010.25.6.924
[14]
Gloster, H.M. and Neal, K. (2006) Skin Cancer in Skin of Color. Journal of the American Academy of Dermatology, 55, 741-760.
[15]
Hussein, M.R. (2005) Skin Cancer in Egypt: A Word in Your Ear. Cancer Biology and Therapy, 4, 593-595. https://doi.org/10.4161/cbt.4.5.1730
[16]
Norval, M., Kellett, P. and Wright, C.Y. (2014) The Incidence and Body Site of Skin Cancers in the Population Groups of South Africa. Photodermatology, Photoimmunology and Photomedicine, 30, 262-265. https://doi.org/10.1111/phpp.12106
[17]
Mseddi, M., et al. (2007) [Epidemio-Clinical Profile of Skin Cancer in Southern Tunisia]. La Tunisie Medicale, 85, 505-508.
[18]
Mohamed, A.A., Mahmuod, S.M., Hassan, M.A., Haj, M.O. and Elnour, K.E.M.H. (2012) Skin Cancer in Dark Skin: A Review of 535 Patients from Sudan. Journal of Advanced Management Science, 2, 8-12.
[19]
Deady, S., Sharp, L. and Comber, H. (2014) Increasing Skin Cancer Incidence in Young, Affluent, Urban Populations: A Challenge for Prevention. The British Journal of Dermatology, 171, 324-331. https://doi.org/10.1111/bjd.12988
[20]
Wu, S., Han, J., Li, W.Q., Li, T. and Qureshi, A.A. (2013) Basal-Cell Carcinoma Incidence and Associated Risk Factors in U.S. Women and Men. American Journal of Epidemiology, 178, 890-897. https://doi.org/10.1093/aje/kwt073
[21]
Evans, S.S., Jih, M.H., Goldberg, L.H. and Kimyai-Asadi, A. (2014) Increased Burden of Melanoma and Nonmelanoma Skin Cancer in Young Women. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery, 40, 1385-1389.
[22]
Betti, R., Inselvini, E., Carducci, M. and Crosti, C. (1995) Age and Site Prevalence OE Histologic Subtypes OE Basal Cell Carcinomas. International Journal of Dermatology, 34, 174-176. https://doi.org/10.1111/j.1365-4362.1995.tb01561.x
[23]
Vantuchova, Y. and Curik, R. (2006) Histological Types of Basal Cell Carcinoma. Scripta Medica, 79, 261-270.
[24]
Scrivener, Y., Grosshans, E. and Cribier, B. (2002) Variations of Basal Cell Carcinomas According to Gender, Age, Location and Histopathological Subtype. The British Journal of Dermatology, 147, 41-47.
https://doi.org/10.1046/j.1365-2133.2002.04804.x
Dourmishev, L.A., Rusinova, D. and Botev, I. (2013) Clinical Variants, Stages, and Management of Basal Cell Carcinoma. Indian Dermatology Online Journal, 4, 12-17. https://doi.org/10.4103/2229-5178.105456
[27]
Dandurand, M., Petit, T., Martel, P., Guillot, B. and Anaes (2006) Management of Basal Cell Carcinoma in Adults Clinical Practice Guidelines. European Journal of Dermatology: EJD, 16, 394-401.
[28]
Barry, J., Oon, S.F., Watson, R. and Barnes, L. (2006) The Management of Basal Cell Carcinomas. Irish Medical Journal, 99, 179-181.
[29]
Marmur, E.S., Schmults, C.D. and Goldberg, D.J. (2004) A Review of Laser and Photodynamic Therapy for the Treatment of Nonmelanoma Skin Cancer. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery, 30, 264-271.
[30]
Trakatelli, M., et al. (2014) Update of the European Guidelines for Basal Cell Carcinoma Management. European Journal of Dermatology: EJD, 24, 312-329.
[31]
Mendenhall, W.M., Amdur, R.J., Hinerman, R.W., Cognetta, A.B. and Mendenhall, N.P. (2009) Radiotherapy for Cutaneous Squamous and Basal Cell Carcinomas of the Head and Neck. The Laryngoscope, 119, 1994-1999.
https://doi.org/10.1002/lary.20608
[32]
Xiong, M.Y., Korgavkar, K., Digiovanna, J.J., Weinstock, M.A. and Veterans Affairs Topical Tretinoin Chemoprevention Trial Group (2014) Fluorouracil and Other Predictors of Morpheaform Basal Cell Carcinoma among High-Risk Patients: The Veterans Affairs Topical Tretinoin Chemoprevention Trial. JAMA Dermatology, 150, 332-334. https://doi.org/10.1001/jamadermatol.2013.5619
[33]
Kropp, L., et al. (2013) Mohs Resection and Postoperative Radiotherapy for Head and Neck Cancers with Incidental Perineural Invasion. American Journal of Otolaryngology, 34, 373-377.
[34]
McCusker, M., et al. (2014) Metastatic Basal Cell Carcinoma: Prognosis Dependent on Anatomic Site and Spread of Disease. European Journal of Cancer, 50, 774-783.
[35]
Black, E.A., Duncan, L.D. and Dieter, R.A. (2013) Pulmonary Metastasis of Basal Cell Carcinoma. The American Surgeon, 79, E221-E222.
[36]
Di Lernia, V., Ricci, C., Zalaudek, I. and Argenziano, G. (2013) Metastasizing Basal Cell Carcinoma. Cutis, 92, 244-246.
[37]
Bucci, T., et al. (2016) Metastatic Basosquamous Carcinoma: Report of Two Cases and Clinicopathological Considerations. International Journal of Surgical Pathology, 24, 726-732. https://doi.org/10.1177/1066896916651493
[38]
Leffell, D.J., Headington, J.T., Wong, D.S. and Swanson, N.A. (1991) Aggressive-Growth Basal Cell Carcinoma in Young Adults. Archives of Dermatology, 127, 1663-1667. https://doi.org/10.1001/archderm.1991.01680100063005
[39]
Hamid, O. and Goldenberg, G. (2013) Identifying Patients at Risk for Recurrent or Advanced BCC. Journal of Drugs in Dermatology: JDD, 12, 1246-1252.
[40]
Gudi, V., et al. (2006) Management of Basal Cell Carcinoma by Surveyed Dermatologists in Scotland. Clinical and Experimental Dermatology, 31, 648-652.
https://doi.org/10.1111/j.1365-2230.2006.02199.x
[41]
East, E., et al. (2016) Morpheaform Basal Cell Carcinomas with Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin. The American Journal of Dermatopathology, 38, 744-750.
https://doi.org/10.1097/DAD.0000000000000541
[42]
Slater, D. and McKee, P. (2002) Minimum Dataset for the Histopathological Reporting of Common Skin Cancers. The Royal College of Pathologists, London, 1-23.
[43]
Tan, W.P., Tan, A.W., Ee, H.L., Kumarasinghe, P. and Tan, S.H. (2008) Melanization in Basal Cell Carcinomas: Microscopic Characterization of Clinically Pigmented and Non-Pigmented Tumours. The Australasian Journal of Dermatology, 49, 202-206. https://doi.org/10.1111/j.1440-0960.2008.00469.x
[44]
Mirowski, G.W., Liu, A.A., Parks, E.T. and Caldemeyer, K.S. (2000) Nevoid Basal Cell Carcinoma Syndrome. Journal of the American Academy of Dermatology, 43, 1092-1109. https://doi.org/10.1067/mjd.2000.107944
[45]
Nilsson, M., et al. (2000) Induction of Basal Cell Carcinomas and Trichoepitheliomas in Mice Overexpressing GLI-1. Proceedings of the National Academy of Sciences of the United States of America, 97, 3438-3443.
https://doi.org/10.1073/pnas.97.7.3438
[46]
D’Errico, M., et al. (2000) UV Mutation Signature in Tumor Suppressor Genes Involved in Skin Carcinogenesis in Xeroderma Pigmentosum Patients. Oncogene, 19, 463-467.
[47]
Kim, M.Y., Park, H.J., Baek, S.C., Byun, D.G. and Houh, D. (2002) Mutations of the p53 and PTCH Gene in Basal Cell Carcinomas: UV Mutation Signature and Strand Bias. Journal of Dermatological Science, 29, 1-9.
[48]
Hahn, H., et al. (1996) Mutations of the Human Homolog of Drosophila Patched in the Nevoid Basal Cell Carcinoma Syndrome. Cell, 85, 841-851.
[49]
Gilbert, S.M., et al. (2017) A Phase I Clinical Trial Demonstrates That nfP2X7 Targeted Antibodies Provide a Novel, Safe and Tolerable Topical Therapy for Basal Cell Carcinoma. The British Journal of Dermatology, 177, 117-124.
https://doi.org/10.1111/bjd.15364
[50]
Busam, K.J. (2010) Dermatopathology. Elsevier Health Sciences.
[51]
Goyal, A., et al. (2016) Cytokeratin 17 Is Highly Sensitive in Discriminating Cutaneous Lymphadenoma (a Distinct Trichoblastoma Variant) from Basal Cell Carcinoma. Journal of Cutaneous Pathology, 43, 422-429.
https://doi.org/10.1111/cup.12700
[52]
Abyaneh, M.-A.Y., et al. (2017) Giant Basal Cell Carcinomas Express Neuroactive Mediators and Show a High Growth Rate: A Case-Control Study and Meta-Analysis of Etiopathogenic and Prognostic Factors. The American Journal of Dermatopathology, 39, 189-194. https://doi.org/10.1097/DAD.0000000000000640
